Last Updated: November 16, 2026

PALTUSOTINE HYDROCHLORIDE - Generic Drug Details

« Back to Dashboard


What are the generic sources for paltusotine hydrochloride and what is the scope of patent protection?

Paltusotine hydrochloride is the generic ingredient in one branded drug marketed by Crinetics and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for PALTUSOTINE HYDROCHLORIDE
International Patents:110
US Patents:9
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 7
Patent Applications: 29
DailyMed Link:PALTUSOTINE HYDROCHLORIDE at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PALTUSOTINE HYDROCHLORIDE
Generic Entry Date for PALTUSOTINE HYDROCHLORIDE*:
Constraining patent/regulatory exclusivity:

TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION

Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PALTUSOTINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Crinetics Pharmaceuticals Inc.PHASE3
Crinetics Pharmaceuticals Inc.Phase 3
Crinetics Pharmaceuticals Inc.Phase 2

See all PALTUSOTINE HYDROCHLORIDE clinical trials

US Patents and Regulatory Information for PALTUSOTINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Crinetics PALSONIFY paltusotine hydrochloride TABLET;ORAL 219070-002 Sep 25, 2025 RX Yes Yes 11,957,674 ⤷  Start Trial ⤷  Start Trial
Crinetics PALSONIFY paltusotine hydrochloride TABLET;ORAL 219070-001 Sep 25, 2025 RX Yes No 9,896,432 ⤷  Start Trial Y Y ⤷  Start Trial
Crinetics PALSONIFY paltusotine hydrochloride TABLET;ORAL 219070-002 Sep 25, 2025 RX Yes Yes 10,597,377 ⤷  Start Trial Y Y ⤷  Start Trial
Crinetics PALSONIFY paltusotine hydrochloride TABLET;ORAL 219070-001 Sep 25, 2025 RX Yes No 11,414,397 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for PALTUSOTINE HYDROCHLORIDE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3484865 C20260018 Finland ⤷  Start Trial
3484865 301394 Netherlands ⤷  Start Trial PRODUCT NAME: PALTUSOTINE IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VORM; REGISTRATION NO/DATE: EU/1/26/2021 20260427
3484865 2026C/739 Belgium ⤷  Start Trial PRODUCT NAME: LA PALTUSOTINE SOUS TOUTES SES FORMES PROTEGEE PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/26/2021 20260423
3484865 LUC50062 Luxembourg ⤷  Start Trial PRODUCT NAME: PALTUSOTINE SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/26/2021 20260427
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.